Mayo Clinic Speakers at American Association for Clinical Chemistry 2012

The Mayo Clinic Department of Laboratory Medicine and Pathology will have multiple moderators and speakers throughout this year's American Association for Clinical Chemistry 2012 Annual Meeting in Los Angeles, Calif. For your reference, information about every Mayo Clinic speaker has been organized below. This year, Mayo Clinic physicians and participating in seven symposia, two short courses, one interactive morning workshop, eight brown bags, two AACC University Courses, and 34 poster presentations.

-

Symposia

Back to Top

Title 32102 eGFR in the Context of Drug Dosing for Pediatric Patients
Date/Time July 16, 2012 from 10:30 a.m.-noon
Type Morning Symposium
Moderator Angela Ferguson, PhD, DABCC, FACB
Children's Mercy Hospitals and Clinics, Kansas City, MO
Pediatric and Maternal-Fetal Division, TDM & Toxicology Division
Level Intermediate
CE Hours 1.5
Intended Audience This session is intended for laboratory personnel, pathologists, and pharmacists involved with reporting of laboratory test results, with interpretation of those results, or involved in the drug dosage for pediatric patients.
Overview The implementation of creatinine standardization has affected the estimation of glomerular filtration rate (eGFR). This session will discuss eGFR topics including how to predict renal drug clearance and assess therapeutic ranges in pediatric patients.
Expected Outcomes After attending this session, participants will be able to: 1) determine the optimal formula to use when calculating drug dosages for children; 2) explain how renal drug clearance is predicted; and 3) discuss the requirements for the determination of therapeutic drug ranges.
Speakers
  • Pediatric eGFR and Drug Dosing: Which Formula Should Be Used?; George Schwartz, MD, University of Rochester Medical Center, Rochester, NY
  • Pediatric Drug Monitoring Reference Ranges - Kids Are Not Small Adults; Thomas Moyer, PhD, DABCC, Mayo Clinic, Rochester, MN
Register http://direct.aacc.org/am/AMProduct.aspx?ID=6959

 

Title 32211 Current Topics in Thyroid Disease
Date/Time July 16, 2012 from 2:30 to 5:00 p.m.
Type Afternoon Symposium
Moderator Michael Hallworth, MA, MSc, MCB, FRCPath
Royal Shrewsbury Hospital, United Kingdom
Level Intermediate
CE Hours 2.5
Intended Audience This session is intended for pathologists, laboratory directors, clinical chemists, technologists, IVD industry scientists and physicians with an interest in thyroid disease.
Overview Thyroid function tests remain the most common endocrine investigation requested by physicians, but can still present considerable interpretative challenges. This session will review recent developments in the understanding of the mechanism of action of thyroid hormones, the evaluation and management of thyroid cancer and the strengths and weaknesses of current assays for the assessment of thyroid function and monitoring thyroid cancer.
Expected Outcomes After attending this session, participants will be able to: 1) summarize recent advances in our understanding of the mechanism of action of thyroid hormones; 2) explain the importance of understanding these actions in development of therapeutic agents for metabolic disorders; 3) discuss current approaches to diagnosis, management and monitoring of patients with thyroid nodules and disseminated thyroid cancer; 4) describe the limitations of currently available tests of thyroid function and assays for thyroglobulin; and 5) implement laboratory strategies to minimize the effect of these limitations including appropriate assay selection.
Speakers
  • Mechanisms of Thyroid Hormone Action; Gregory Brent, BS, MD, David Geffen School of Medicine at UCLA
  • Thyroid Function Tests - Are They Fit for Purpose?; Carole Spencer, PhD, MT, FACB, University of Southern California, Pasadena
  • Evaluation and Management of Thyroid Cancer; Bryan McIver, MB, PhD, Mayo Clinic, Rochester, MN
Register http://direct.aacc.org/am/AMProduct.aspx?ID=6963

 

Title 32212 Coronary Artery Disease, Lipids and Genetic Testing
Date/Time July 16, 2012 from 2:30 to 5:00 p.m.
Type Afternoon Symposium
Moderator Allan Jaffe, MD
Mayo Clinic, Rochester

American College of Cardiology
Level Intermediate
CE Hours 2.5
Intended Audience This session is intended for clinical chemists, laboratorians, clinical pathologists, cardiologists and others in related fields who are interested in the genetics of coronary artery disease.
Overview There are increasing data suggesting that defining a genetic propensity to lipid abnormalities and coronary artery disease can be useful in the diagnosis, management, triage and prevention of cardiovascular disease. Nonetheless, such testing is in some areas being used extensively. Clinicians receive a large number of messages concerning the use of such testing.
Expected Outcomes After attending this sessions, participants will be able to: 1) describe the tests clinically available to characterize a propensity for coronary artery disease; 2) summarize the frequency of familial hyperlipidemia and tests available to define its genetic proclivity; and 3) define the criteria for use of this testing as it relates to the existing testing guidelines.
Speakers
  • Genetics of Coronary Artery Disease; Robert Roberts, MD, University of Ottawa Heart Institute, Ottawa, Canada
  • Implementing Laboratory Genetic Testing; Heidi Rehm, PhD, ABMG Molecular Genetics, Harvard Medical School, Boston, MA
  • Prevalance, Genetics, Diagnosis and Screening Recommendation for Familial Hyperlipedemia; Lisa Cooper Hudgins, MD, The Rogosin Institute/Weill Cornell Medical College, New York
Register http://direct.aacc.org/am/AMProduct.aspx?ID=6971

 

Title 32213 Genetics in Hematological Malignancies: Contribution to Diagnosis, Prognosis and Treatment
Date/Time July 16, 2012 from 2:30 to 5:00 p.m.
Type Afternoon Symposium
Moderator Carlo Brugnara, MD
Children's Hospital, Boston, MA
Level Intermediate
CE Hours 2.5
Intended Audience This session is intended for clinical chemists, clinical and molecular pathologists, medical technologists, IVD industry scientists, geneticists and others interested in learning about how molecular diagnostic techniques are used in the clinical management of patients with hematological malignancies.
Overview The session will present an overview of how novel molecular genetic studies affect the diagnosis, prognosis and treatment of hematological malignancies. Three speakers will discuss how these technologies apply to disease management in acute leukemia, myelodysplastic and myeloproliferative neoplasms, and multiple myeloma.
Expected Outcomes After attending this session, participants will be able to: 1) describe newly developed technique for molecular diagnosis of hematological diseases; 2) evaluate a range of different diagnostic approaches and how they can be integrated into diagnostic/prognostic criteria; 3) understand how molecular diagnostic parameters can be used to predict responsiveness to therapy in individual patients; and 4) describe the availability of novel targeted arrays as cost-effective tools for diagnosis and monitoring of diseases and treatment.
Speakers
  • Acute Leukemias; Ross Levine, MD, Memorial Sloan-Kettering Cancer Center, New York
  • Myeloproliferative Neoplasms and Myelodysplastic Syndromes; Ayalew Tefferi, MD, Mayo Clinic, Rochester, MN
  • B-Cell Lymphomas; Adam Bagg, MD, University of Pennsylvania, Philadelphia
Register http://direct.aacc.org/am/AMProduct.aspx?ID=6969

 

Title 33125 Applications for Measurement of Arginine and its Methylated Derivatives (ADMA and SDMA) in Adult and Pediatric Disease
Date/Time July 17, 2012 from 10:30 a.m.-noon
Type Morning Symposium
Moderator Shannon Haymond, PhD, DABCC
Children's Memorial Hospital, Chicago, IL
Pediatric and Maternal-Fetal Division
Level Basic
CE Hours 2.5
Intended Audience This session is intended for clinical laboratory scientists, medical technologists, clinicians, pathologists, IVD industry scientists, medical directors, laboratory directors and clinical chemists.
Overview Recent advances have associated methylated arginine derivatives, ADMA and SDMA, with adverse outcomes in pediatric and adult disease. ADMA and SDMA are linked to endothelial and vascular dysfunction through their role in the arginine-nitric oxide pathway. Thus, there is increasing interest in measuring arginine, ADMA, and SDMA for clinical purposes and in the development of therapies targeted at modifying ADMA and SDMA. This session will include a review of the biochemistry and pathophysiology of arginine and its methylated derivatives and each speaker will highlight the clinical significance of these biomarkers for a particular disorder (kidney and cardiovascular disease) by reviewing the current state of knowledge and comparing what is known in adult and pediatric populations.
Expected Outcomes After attending this session, participants will be able to: 1) describe the biochemistry and pathophysiology of arginine, ADMA and SDMA; 2) discuss the roles of arginine, ADMA and SDMA for predicting malnutrition and disease progression in children and adults with kidney disease; 3) summarize the evidence establishing ADMA as an independent risk factor for cardiovascular disease and the use of arginine supplementation to reduce cardiac dysfunction without inflammation; and 4) describe the analytical methods for measurement of arginine, ADMA and SDMA and discuss the impact of the lack of standardization among these methods.
Speakers
  • Measurement and Utilization of Arginine, ADMA and SDMA in Kidney Disease; Shannon Haymond, PhD, DABCC, Children's Memorial Hospital, Chicago, IL
  • ADMA as a Cardiovascular Risk Factor; Amy Saenger, PhD, DABCC, Mayo Clinic, Rochester, MN
Register http://direct.aacc.org/am/AMProduct.aspx?ID=6959

 

Title 34217 The Impact of Lot-to-Lot Variation in Immunoassay Test Accuracy
Date/Time July 18, 2012 from 2:30 to 5:00 p.m.
Type Afternoon Symposium
Moderator Marjorie Bon Homme, PhD
David Geffen School of Medicine at UCLA
UK National External Quality Assessment Service (UK NEQAS), Clinical & Diagnostic Immunology Division, Industry Division
Level Intermediate
CE Hours 2.5
Intended Audience This session is intended for laboratory directors, clinical chemists, clinical pathologists, technologists, IVD industry scientists, regulatory agencies, proficiency service providers and commercial QC manufacturers.
Overview Lot-to-lot variation can be a significant challenge in generating quality laboratory results. Until expert guidelines are developed it is important to understand how stakeholders deal with this issue. The purpose of this session is to provide an understanding of practical solutions to control the impact of lot-to-lot variation.
Expected Outcomes After attending this session, participants will be able to: 1) describe the manufacturer’s perspective on overcoming the challenges of producing consistent immunoassay reagent and calibrator lots; 2) describe quality control materials (commercial or pooled samples) and present some practical methods that may be adopted by an institution to identify and deal with lot-to-lot variation; and 3) describe the clinical implications of lot to lot variability.
Speakers
  • Manufacturer’s Perspective – The Manufacturer’s Challenging Role in Assuring Lot to Lot Consistency; Andrea Rose, PhD, MBA, Roche, Indianapolis, IN
  • Laboratory’s Perspective – The Clinical Impact and Laboratory Burden of Lot to Lot Variability; Alicia Algeciras-Schimnich, PhD, DABCC, Mayo Clinic, Rochester, MN
  • Proficiency Testing Service Perspective –The Role of Proficiency Testing Surveys in Assessing Reagent Lot Variability; Catharine Sturgeon, PhD, FACB, FRCPath, The Royal Infirmary of Edinburgh, United Kingdom
Register http://direct.aacc.org/am/AMProduct.aspx?ID=7135

 

Title 35103 New Developments in Metabolic Disease Testing
Date/Time July 19, 2012 from 9:30 a.m.-noon
Type Morning Symposium
Moderator Dennis Dietzen, PhD, DABCC
Washington University School of Medicine, Saint Louis, MO
Level Intermediate
CE Hours 2.5
Intended Audience This session is intended for physicians, laboratory directors, clinical chemists, clinical pathologists, medical technologists, and IVD industry scientists.
Overview This session will illustrate the latest developments in using multi-analyte metabolic profiles traditionally applied to detect and define inborn errors of metabolism. The session will describe: 1) New computational methods applied to biochemical data that enhance accuracy of the diagnosis of inborn metabolic disorders; 2) Non-traditional applications of metabolite profiles in the assessment of maternal health and liver disease; and, 3) the measurement and clinical utility of cellular metabolites that have therefore not been utilized to characterize metabolic disorders.
Expected Outcomes After attending this session, participants will be able to: 1) locate and utilize tools for manipulating metabolomic profiles to detect disease; 2) describe the metabolic characteristics of disease states other than inborn metabolic disorders; and 3) explain the role that coenzyme A esters will play in clarifying the pathophysiology and diagnosis of disrupted cellular metabolism.
Speakers
  • Clinical Utility of Post-Analytical Tools for the Interpretation of Complex Metabolic Profiles; Piero Rinaldo, MD, PhD, Mayo Clinic, Rochester, MN
  • Follow-up Testing and Beyond: New Applications for Metabolic Profiling; Dennis Dietzen, PhD, DABCC, Washington University School of Medicine, Saint Louis, MO
  • Measurement of Intracellular Coenzyme A Species: A New Class of Metabolic Disease Biomarkers; Michael Bennett, PhD, DABCC, University of Pennsylvania and Children's Hospital of Philadelphia
Register http://direct.aacc.org/am/AMProduct.aspx?ID=7205

Short Courses

Back to Top

Title 191010 Adrenal Hypertension: Interpretation of Biochemical Tests
Date/Time July 15, 2012 from 1:30 to 4:00 p.m.
Type Afternoon Symposium
Moderator Andrew Don-Wauchope, MBBCh,BScMed(Hons), MD, FRCP Edin, FCPath(SA), FRCPath, FRCPC
McMaster University, Hamilton, Canada
Level Intermediate
CE Hours 2.5
Intended Audience This session is intended for pathologists, lab directors, clinical chemists, managers and technologists.
Overview This workshop will inform attendees about the role of the laboratory in the diagnosis of adrenal hypertension. The speakers will use a mixture of didactic presentations and interactive case reports to describe the use of renin, aldosterone, cortisol and catecholamines in the diagnosis of hypertension due to adrenal disease.
Expected Outcomes After attending this session, participants will be able: 1) to interpret the biochemical tests used in the laboratory identification of adrenal hypertension; 2) to discuss the renin: aldosterone ratio; 3) to evaluate the methods for measuring catecholamines and catecholamine metabolites; 4) to identify issues related to cortisol testing; and 5) to recognize the potential pitfalls of these tests
Speakers
  • Cortisol; Patrick Twomey, BSc, MBBCh, FRCPath, EurClinChem, FACB, Ipswich Hospital, United Kingdom
  • Metanephrines; Ravinder Singh, PhD, DABCC, FACB, Mayo Clinic, Rochester, MN
  • Renin and Aldosterone; Daniel Holmes, BSc, MD, FRCPC, St Paul's Hosp, Vancouver, BC, Canada
Register http://direct.aacc.org/am/AMProduct.aspx?ID=6939

 

Title 191012 Laboratory-Driven Testing Algorithms: A Strategy to Improve Ordering Accuracy, Efficiency, and Utilization
Date/Time July 15, 2012 from 1:30 to 4:00 p.m.
Type Afternoon Symposium
Moderator Paula Santrach, MD, FCAP, FACB
Mayo Clinic, Rochester, MN
Level Intermediate
CE Hours 2.5
Intended Audience This session is intended for pathologists, laboratory directors, clinical chemists, laboratory technologists, and laboratory managers who are interested in cost effective laboratory testing.
Overview Cost-effective laboratory testing is a necessary strategy for health care reform. Laboratory-driven testing algorithms for bone marrow examination, celiac disease, and evaluation for parasitic infection will be presented as examples of how to improve ordering practices and decrease health care costs. Algorithm development, implementation, outcomes and lessons learned will be discussed.
Expected Outcomes After attending this session, participants will be able to: 1) outline an approach to the development and implementation of laboratory-driven testing algorithms based on clinical questions; and 2) assess the potential outcomes of this approach on ordering practices and cost.
Speakers
  • Testing Algorithms for the Diagnosis of Celiac Disease
    Melissa Snyder, PhD, DABCC, Mayo Clinic, Rochester, MN
  • Diagnostically Efficient and Cost Effective Test Utilization for Hematologic Malignancies from Blood and Bone Marrow Specimens
    Paul Kurtin, MD, Mayo Clinic, Rochester, MN
  • Algorithm for Parasitic Investigation of Stool Specimens
    Bobbi Pritt, MD, Mayo Clinic, Rochester, MN
Register http://direct.aacc.org/am/AMProduct.aspx?ID=6941

Morning Interactive Workshops

Back to Top

Title 23109 Responding to Laboratory Errors That Impact Multiple Patients: A Practical Approach
Date/Time July 17, 2012 from 10:30 a.m. to noon
Type Morning Interactive Workshop
Moderator Nikola Baumann, PhD, DABCC
Mayo Clinic, Rochester, MN

Developed by the Laboratory Patient Safety Committee of the AACC MSPSD
Level Intermediate
CE Hours 1.5
Intended Audience This session is intended for laboratory directors, pathologists, managers, supervisors and quality specialists.
Overview In high-volume laboratories, there is potential for systematic errors to impact numerous patient results before the error is detected. This session will teach practical approaches for responding to large-scale testing errors and provide participants with a toolkit for assessing risk, determining corrective action, and appropriately communicating when these issues occur.
Expected Outcomes After attending this session, participants will be able to: 1) describe a practical, systematic approach and develop tools for responding to laboratory testing errors; 2) assess the clinical significance of errors and risk of adverse consequences to patients; 3) evaluate the need for corrective action and appropriate communication; and 4) implement a process for responding to errors in their laboratories and institutions.
Speakers
  • Laboratory Errors that Impact Multiple Patients: Case Discussions; Nikola Baumann, PhD, DABCC, Mayo Clinic, Rochester, MN
  • Investigating and Responding to Errors in Laboratory Testing: A Toolkit; Paula Santrach, MD, FCAP, FACB, Mayo Clinic, Rochester, MN
Register http://direct.aacc.org/am/AMProduct.aspx?ID=7039  

Brown Bags

Back to Top

Title 42101 Neuron Specific Enolase Quantification: Utility and Caveats for Prognosis in Post-Anoxic Coma
Date/Times July 16, 2012 from 7:30 to 8:30 a.m. AND 12:30 to 1:30 p.m.
Type Brown Bag
Speaker Jonathan Hoyne, PhD
Mayo Clinic, Jacksonville, FL
Level Basic
CE Hours 1
Intended Audience The session is intended for pathologists, lab directors, clinical chemists, technologists and others with a professional interest in laboratory assessment and clinical management of patients in post-anoxic coma.
Overview This session will review the current knowledge of neuron specific enolase (NSE) and discuss assay utility and test performance concerns.
Expected Outcomes After attending this session, participants will be able to: 1) describe the role of NSE in the assessment of prognosis in post-resuscitation, post-anoxic coma; 2)explain the basis of the AAN Practice Parameter; 3) describe the effects of hemolysis; and 4)articulate the effects of lack of standardization of NSE test results.
Register http://direct.aacc.org/am/AMProduct.aspx?ID=6976

 

Title 42106 Introducing New Technology to the Lab: Dealing With Education, Familiarization, and Fear
Date/Times July 16, 2012 from 7:30 to 8:30 a.m. AND 12:30 to 1:30 p.m.
Type Brown Bag
Speaker Christine Snozek, PhD, DABCC, FACB
Mayo Clinic, Scottsdale, AZ
Level Basic
CE Hours 1
Intended Audience This session is intended for laboratory directors, clinical chemists, and technologists.
Overview Complex analytical platforms are growing rapidly in clinical laboratories. Most education sessions focus on technical aspects, ignoring the difficulty of introducing these technologies to laboratories accustomed to automated platforms. This session focuses on smoothing the process of introducing complex analytical instruments, using tools such as surveys and educational presentations.
Expected Outcomes After attending this session, participants will be able to: 1) detail the challenges inherent in introducing a novel technology into a laboratory; and 2) list strategies for assessing and improving the laboratory staff’s comfort level with the new platform.
Register http://direct.aacc.org/am/AMProduct.aspx?ID=7002

 

Title 42120 Macroenzymes: Diagnostic Dilemmas and Laboratory Solutions
Date/Times July 16, 2012 from 7:30 to 8:30 a.m. AND 12:30 to 1:30 p.m.
Type Brown Bag
Speaker Leslie Donato, PhD
Mayo Clinic, Rochester, MN
Level Basic
CE Hours 1
Intended Audience This session is intended for laboratory directors, clinical chemists, and technologists.
Overview Macroenzymes have been identified for many serum enzymes and they can cause diagnostic dilemmas. This course will focus on macroenzymes- what are they, why do they cause confusion in test interpretation, and how can laboratories handle requests for macroenzyme testing. An example of macroenzyme testing validation for macro aspartate aminotransferase will be discussed.
Expected Outcomes After this session, participants will be able to: 1) describe what a macroenzyme is and what problems it can cause; and 2) develop validation studies to establish macroenzyme testing in their laboratory.
Register http://direct.aacc.org/am/AMProduct.aspx?ID=6996

 

Title 42130 Monitoring Heparin Anticoagulation: Should We Measure Effect or Concentration?
Date/Times July 16, 2012 from 7:30 to 8:30 a.m. AND 12:30 to 1:30 p.m.
Type Brown Bag
Speaker Paula Santrach, MD, FCAP, FACB
Mayo Clinic, Rochester, MN
Level Intermediate
CE Hours 1
Intended Audience This session is intended for pathologists, laboratory directors, clinical chemists, laboratory managers, and laboratory technologists.
Overview This session will review basic pharmacology for unfractionated and low molecular weight heparin. Appropriate tests and targets as well as their evidence base will be outlined for clinical scenarios involving cardiopulmonary bypass, percutaneous coronary intervention, acute treatment of venous thromboembolism (VTE), VTE prophylaxis, and heparin resistance.
Expected Outcomes After attending this session, participants will be able to: 1) select the best heparin monitoring strategy for a variety of clinical situations; and 2) detect the presence of heparin resistance and make recommendations for management.
Register http://direct.aacc.org/am/AMProduct.aspx?ID=7026

 

Title 43118 Body Fluid Testing in the Clinical Laboratory
Date/Times July 17, 2012 from 7:30 to 8:30 a.m. AND 12:30 to 1:30 p.m.
Type Brown Bag
Speaker Darci Block, PhD, DABCC
Mayo Clinic, Rochester, MN
Level Basic
CE Hours 1
Intended Audience This session is intended for pathologists, laboratory directors, clinical chemists, technologists, residents, fellows, and students.
Overview This session will focus on the unique challenges for measurement of chemistry analytes in body fluids other than blood or urine. The regulatory requirements for clinical testing and reporting of body fluid results, common clinical scenarios where body fluid testing may be appropriate, and validation strategies will be discussed.
Expected Outcomes After attending this session, participants will be able to: 1) identify the regulatory requirements and potential barriers for performing clinical testing on body fluids; and 2) evaluate solutions for maintaining compliance in body fluid testing.
Register http://direct.aacc.org/am/AMProduct.aspx?ID=7059

 

Title 43120 Impact of Glycemic Target on Accuracy Needs for Glucose Monitors in the Intensive Care Unit
Date/Times July 17, 2012 from 7:30 to 8:30 a.m. AND 12:30 to 1:30 p.m.
Type Brown Bag
Speaker Brad Karon, MD, PhD, FCAP, FACB
Mayo Clinic, Rochester, MN
Level Intermediate
CE Hours 1
Intended Audience This session is intended for laboratory directors, point-of-care coordinators, nurses, physicians, laboratorians, medical technologists, and others interested in learning about best practices in development and management of point-of-care glycemic control programs.
Overview Tight glycemic control may improve outcomes for ICU patients. This session will examine the impact of glycemic target on the needs for glucose monitor accuracy. Empiric data on the relationship between glycemic range and incidence of hypoglycemia will be reviewed. Information gained from error simulation models will also be discussed.
Expected Outcomes After this session, participants will be able to: 1) weigh the benefits of tight glycemic control against the adverse effects of hypoglycemia; 2) list various approaches to defining accuracy requirements for glucose meters used during glycemic control; and 3) define the role that glycemic target plays on accuracy needs for glucose monitors in the ICU.
Register http://direct.aacc.org/am/AMProduct.aspx?ID=7075

 

Title 44106 Utility of Allergen-Specific IgEs and Allergic Disease
Date/Times July 18, 2012 from 7:30 to 8:30 a.m. AND 12:30 to 1:30 p.m.
Type Brown Bag
Speaker Melissa Snyder, PhD, DABCC
Mayo Clinic, Rochester, MN
Level Intermediate
CE Hours 1
Intended Audience This session is intended for laboratory directors, clinical chemists, clinical immunologists and clinical laboratory technologists.
Overview Allergic disease is complex and difficult to diagnose. This session will review the pathophysiology of allergic disease, strategies for the diagnostic work-up for patients with suspected disease, and analytical methods for measurement of allergen-specific IgE antibodies and their clinical utility.
Expected Outcomes After attending this session, participants will be able to: 1) describe a type I hypersensitivity reaction and the role of IgE antibodies; 2) list the analytical methods used for the in vitro assessment of allergen-specific IgEs in the diagnosis of allergic disease; and 3) define the optimal testing strategies for children and adults suspected of having an allergic disease.
Register http://direct.aacc.org/am/AMProduct.aspx?ID=7178

 

Title 44123 Vitamin D Endocrine System-Beyond Bones
Date/Times July 18, 2012 from 7:30 to 8:30 a.m. AND 12:30 to 1:30 p.m.
Type Brown Bag
Speaker Ravinder Singh, PhD, DABCC, FACB
Mayo Clinic, Rochester, MN
Level Basic
CE Hours 1
Intended Audience This session is intended for pathologists, laboratory directors, clinical chemists, technologists and IVD industry scientists.
Overview The understanding of Vitamin D physiology has exponentially increased in last few years. Vitamin D deficiency has been associated with numerous disorders. In this session, clinical literature will be reviewed and the role of vitamin D deficiency in various diseases will be discussed.
Expected Outcomes After attending this session, participants will be able to: 1) understand the reason for increased interest in Vitamin D testing; 2) differentiate among various methods for analysis of Vitamin D; and 3) critically evaluate the correlation between Vitamin D deficiency and various diseases.
Register http://direct.aacc.org/am/AMProduct.aspx?ID=7182

AACC University

Back to Top

Title 191010 Adrenal Hypertension: Interpretation of Biochemical Tests
Date/Time July 15, 2012 from 1:30 to 4:00 p.m.
Type Afternoon Short Course
Moderator Andrew Don-Wauchope, MBBCh,BScMed(Hons), MD, FRCP Edin, FCPath(SA), FRCPath, FRCPC
McMaster University, Hamilton, Canada 
Level Intermediate
CE Hours 2.5
Intended Audience This session is intended for pathologists, lab directors, clinical chemists, managers and technologists.
Overview This workshop will inform attendees about the role of the laboratory in the diagnosis of adrenal hypertension. The speakers will use a mixture of didactic presentations and interactive case reports to describe the use of renin, aldosterone, cortisol and catecholamines in the diagnosis of hypertension due to adrenal disease.
Expected Outcomes After attending this session, participants will be able: 1) to interpret the biochemical tests used in the laboratory identification of adrenal hypertension; 2) to discuss the renin: aldosterone ratio; 3) to evaluate the methods for measuring catecholamines and catecholamine metabolites; 4) to identify issues related to cortisol testing; and 5) to recognize the potential pitfalls of these tests.
Speakers
  • Cortisol; Patrick Twomey, BSc, MBBCh, FRCPath, EurClinChem, FACB, Ipswich Hospital, United Kingdom
  • Metanephrines; Ravinder Singh, PhD, DABCC, FACB, Mayo Clinic, Rochester, MN
  • Renin and Aldosterone; Daniel Holmes, BSc, MD, FRCPC, St Paul's Hosp, Vancouver, BC, Canada
Register http://direct.aacc.org/am/AMProduct.aspx?ID=6939

 

Title 191012 Laboratory-Driven Testing Algorithms: A Strategy to Improve Ordering Accuracy, Efficiency, and Utilization
Date/Time July 15, 2012 from 1:30 to 4:00 p.m.
Type Afternoon Short Course
Moderator Paula Santrach, MD, FCAP, FACB
Mayo Clinic, Rochester, MN
Level Intermediate
CE Hours 2.5
Intended Audience This session is intended for pathologists, laboratory directors, clinical chemists, laboratory technologists, and laboratory managers who are interested in cost effective laboratory testing.
Overview Cost-effective laboratory testing is a necessary strategy for health care reform. Laboratory-driven testing algorithms for bone marrow examination, celiac disease, and evaluation for parasitic infection will be presented as examples of how to improve ordering practices and decrease health care costs. Algorithm development, implementation, outcomes and lessons learned will be discussed.
Expected Outcomes After attending this session, participants will be able to: 1) outline an approach to the development and implementation of laboratory-driven testing algorithms based on clinical questions; and 2) assess the potential outcomes of this approach on ordering practices and cost.
Speakers
  • Testing Algorithms for the Diagnosis of Celiac Disease; Melissa Snyder, PhD, DABCC, Mayo Clinic, Rochester, MN
  • Diagnostically Efficient and Cost Effective Test Utilization for Hematologic Malignancies from Blood and Bone Marrow Specimens; Paul Kurtin, MD, Mayo Clinic, Rochester, MN
  • Algorithm for Parasitic Investigation of Stool Specimens; Bobbi Pritt, MD, Mayo Clinic, Rochester, MN
Register http://direct.aacc.org/am/AMProduct.aspx?ID=6941

Poster Presentations

Back to Top

Tue, Jul 17, 2:00 - 4:30 PM
B-125/B-125 - Using Lean Engineering Principles and Pre-Analytical Process Improvements to Decrease Specimen Processing Time
S. P. Cedotal, S. Ostby, J. Wees, C. Yoch, L. Jonsgaard, M. Poncelet, T. Scott, C. Clayton, J. Carlson, T. Jennings, D. Block, N. Baumann. Mayo Clinic, Rochester, MN, Poster Session
08. Technology/Design Development
Tue, Jul 17, 2:00 - 4:30 PM
Tue, Jul 17, 2:00 - 4:30 PM
B-97/B-97 - Reference ranges for thyroid function tests derived from healthy subjects with normal thyroid examination and thyroid ultrasound.
L. J. Ouverson, L. L. Kosok, D. S. Dean, M. R. Castro, M. N. Stan, V. Fatourechi, D. L. Howe-Clayton, J. C. Morris, N. A. Baumann, B. McIver, G. G. Klee. Mayo Clinic, Rochester, MN, Poster Session
07. Endocrinology/Hormones
Tue, Jul 17, 2:00 - 4:30 PM
Thu, Jul 19, 9:30 AM - 12:00 PM
E-167/E-167 - Has the Incidence of Intravenous Contrast Induced Nephropathy Been Overestimated?
J. S. McDonald, R. J. McDonald, J. P. Bida, R. E. Carter, C. J. Fleming, S. Misra, E. E. Williamson, D. F. Kallmes.Mayo College of Medicine, Rochester, MN, Poster Session
21. Clinical Studies/Outcomes
Thu, Jul 19, 9:30 AM - 12:00 PM
Wed, Jul 18, 10:00 AM - 12:30 PM
C-53/C-53 - Candidate Reference Method for measuring blood concentrations of Prostate Specific Antigen (PSA) using immuno-extraction, trypsin digestion and tandem mass spectrometry
E. W. Klee1, O. P. Bondar1, S. A. Trushin1, M. K. Goodmanson1, E. J. Bergstralh1, R. J. Singh1, L. Anderson2, G. G. Klee11Mayo Clinic, Rochester, MN, 2Plasma Proteome Institute, Washington, DC, Poster Session
10. Cancer/Tumor Markers
Wed, Jul 18, 10:00 AM - 12:30 PM
Tue, Jul 17, 2:00 - 4:30 PM
B-71/B-71 - Development of Reference Method for Measuring Binding of Sex Hormone Binding Globulin (SHBG) to Sex Hormones in Human Serum.
S. A. Trushin1, O. P. Bondar1, A. H. Fauq2, E. W. Klee1, R. J. Singh1, J. D. Veldhuis1, G. G. Klee11Mayo Clinic College of Medicine, Rochester, MN,2Mayo Clinic College of Medicine, Jacksonville, FL, Poster Session
07. Endocrinology/Hormones
Tue, Jul 17, 2:00 - 4:30 PM
Wed, Jul 18, 2:00 - 4:30 PM
D-55/D-55 - Comparative Performance of Two Whole Blood Point-of-Care Lipid Analyzers to CDC-Certified Laboratory Methods
L. J. Donato, G. R. Deobald, A. M. Wockenfus, J. M. Hornseth, B. S. Karon, A. K. Saenger. Mayo Clinic, Rochester, MN, Poster Session
15. Point-of-Care Testing
Wed, Jul 18, 2:00 - 4:30 PM
Wed, Jul 18, 10:00 AM - 12:30 PM
C-137/C-137 - Histamine Measurement in Urine using Selective Reaction Monitoring Ion-Pairing LC-MS/MS
J. Hines1, E. Kaleta1, K. Cradic1, Z. Cao2, A. Algeciras-Schimnich1, S. Grebe1, R. Singh11Mayo Clinic, Rochester, MN, 2New York State Department of Health, Albany, NY, Poster Session
12. Immunology
Wed, Jul 18, 10:00 AM - 12:30 PM
Tue, Jul 17, 10:00 AM - 12:30 PM
A-46/A-46 - Oxalate analysis of hemodialysate
N. V. Voskoboev, S. L. Wannarka, J. B. Olson, D. S. Milliner, T. S. Larson, J. C. Lieske. Mayo Clinic, Rochester, MN, Poster Session
02. Factors Affecting Test Results
Tue, Jul 17, 10:00 AM - 12:30 PM
Wed, Jul 18, 2:00 - 4:30 PM
D-111/D-111 - Comparison of Serum Methotrexate Concentration by EMIT, FPIA, and LC-MS/MS
R. C. Benirschke1, T. Hartman1, M. Bjergum1, C. Snozek2, L. Langman1.1Mayo Clinic, Rochester, MN, 2Mayo Clinic, Scottsdale, AZ, Poster Session
17. TDM/Toxicology/DAU
Wed, Jul 18, 2:00 - 4:30 PM
Wed, Jul 18, 10:00 AM - 12:30 PM
C-36/C-36 - Determination of cutoff values for Carcinoembryonic Antigen (CEA), Alpha-Fetoprotein (AFP), and Cancer Antigen 19-9 (CA19-9) concentrations in peritoneal fluid to distinguish between malignant and benign etiologies
E. Kaleta, N. Tolan, K. Ness, A. Algeciras-Schimnich. Mayo Clinic, Rochester, MN, Poster Session
10. Cancer/Tumor Markers
Wed, Jul 18, 10:00 AM - 12:30 PM
Tue, Jul 17, 2:00 - 4:30 PM
B-151/B-151 - Evaluation of Radiometer ABL800, Radiometer ABL90 FLEX, and IL GEM 4000 Premier for Blood Gas, Electrolyte, and Metabolite Testing
A. M. Wockenfus, K. J. Hartung, C. D. Koch, B. J. Krekelberg, B. S. Karon.Mayo Clinic, Rochester, MN, Poster Session
09. Electrolytes/Blood Gas/Metabolites
Tue, Jul 17, 2:00 - 4:30 PM
Wed, Jul 18, 2:00 - 4:30 PM
D-49/D-49 - Evaluation of the Fisher Sure -Vue Signature Mono, Inverness Medical Acceava Mono Cassette, and Beckman Coulter ICON Mono test kits
N. K. Myhre, C. D. Koch, A. L. Larson, M. J. Binnicker, B. S. Karon. Mayo Clinic Rochester, Rochester, MN, Poster Session
15. Point-of-Care Testing
Wed, Jul 18, 2:00 - 4:30 PM
Tue, Jul 17, 10:00 AM - 12:30 PM
A-130/A-130 - Improving PGx Testing by Determining the Cis/Trans Orientation of Multiple Gene Variants
J. M. Skierka, J. L. Black, D. L. Walker, S. E. Peterson, D. J. O'Kane. Mayo Clinic, Rochester, MN, Poster Session
04. Molecular Pathology/Probes
Tue, Jul 17, 10:00 AM - 12:30 PM
Wed, Jul 18, 2:00 - 4:30 PM
D-11/D-11 - Measurement of pyridoxal 5-phosphate and pyridoxic acid in human plasma by liquid chromatography-tandem mass spectrometry
D. M. Garby1, A. H. Fauq2, R. DelRosso1, L. A. Cheryk11Mayo Medical Laboratories, Andover, MA,2Mayo Chemical Synthesis Core Facility, Jacksonville, FL, Poster Session
14. Nutrition/Trace Metals/Vitamins
Wed, Jul 18, 2:00 - 4:30 PM
Tue, Jul 17, 10:00 AM - 12:30 PM
A-57/A-57 - Reducing the rejection rate of NSE by detecting low hemoglobin in serum and cerebrospinal fluid using Nanodrop spectrophotometer
N. Vidal-Folch, N. V. Tolan, A. Algeciras-Schimnich, R. J. Singh, S. K. Grebe. Mayo Clinic, Rochester, MN, Poster Session
02. Factors Affecting Test Results
Tue, Jul 17, 10:00 AM - 12:30 PM
Tue, Jul 17, 2:00 - 4:30 PM
B-103/B-103 - Strategy for the development of a mass spectrometry assay for measuring sex hormone binding globulin (SHBG) in human serum
G. G. Klee1, O. P. Bondar1, E. W. Klee1, S. A. Trushin1, L. Anderson2, R. J. Singh11Mayo Clinic, Rochester, MN, 2Plasma Proteome Institute, Washington DC, DC, Poster Session
07. Endocrinology/Hormones
Tue, Jul 17, 2:00 - 4:30 PM
Wed, Jul 18, 10:00 AM - 12:30 PM
C-82/C-82 - Total and Allele-Specific Quantitation of Alpha-1-Antitrypsin by Mass Spectrometry
L. J. Donato, R. M. Karras, J. A. Katzmann, D. L. Murray, M. R. Snyder.Mayo Clinic, Rochester, MN, Poster Session
11. Mass Spectrometry Applications
Wed, Jul 18, 10:00 AM - 12:30 PM
Wed, Jul 18, 10:00 AM - 12:30 PM
C-89/C-89 - Accurate Mass Analysis of Monoclonal Immunoglobulin Light Chains in Serum Using Electrospray Ionization-LC-Time-of-Flight Mass Spectrometry
D. R. Barnidge, J. A. Katzmann, M. R. Snyder, D. L. Murray. Mayo Clinic, Rochester, MN, Poster Session
11. Mass Spectrometry Applications
Wed, Jul 18, 10:00 AM - 12:30 PM
Thu, Jul 19, 9:30 AM - 12:00 PM
E-74/E-74 - Are Volumetric Pipettes Required for Preparing Quality Control Materials?
L. J. Ouverson, C. A. Wittwer, N. A. Baumann, D. R. Block. Mayo Clinic, Rochester, MN, Poster Session
19. Management
Thu, Jul 19, 9:30 AM - 12:00 PM
Wed, Jul 18, 10:00 AM - 12:30 PM
C-57/C-57 - Examination of Thyroglobulin Iodination States and Quantitative Usefulness for Clinical Thyroid Cancer Diagnostics
B. C. Netzel1, B. L. Simons2, S. Mollah2, D. R. Barnidge1, R. J. Singh1, S. K. Grebe11Mayo Clinic and Foundation, Rochester, MN, 2AB Sciex, Foster City, CA, Poster Session
10. Cancer/Tumor Markers
Wed, Jul 18, 10:00 AM - 12:30 PM
Wed, Jul 18, 10:00 AM - 12:30 PM
C-204/C-204 - Identifying pre-analytic variables that contribute to hemolysis in neonatal blood specimens: sample collection site, transportation method and lipid emulsion infusion status.
N. V. Tolan, E. J. Kaleta, B. S. Karon, N. A. Baumann. Mayo Clinic, Rochester, MN, Poster Session
13. Pediatric/Fetal Clinical Chemistry
Wed, Jul 18, 10:00 AM - 12:30 PM
Wed, Jul 18, 10:00 AM - 12:30 PM
C-40/C-40 - Investigation of Potential Interferences in an Automated Assay for Chromogranin A on the ThermoFisher Scientific BRAHMS KRYPTOR Compact PLUS
C. M. Preissner, S. C. Bryant, M. S. Finseth, S. K. Grebe. Mayo Foundation, Rochester, MN, Poster Session
10. Cancer/Tumor Markers
Wed, Jul 18, 10:00 AM - 12:30 PM
Tue, Jul 17, 2:00 - 4:30 PM
B-164/B-164 - Validating Normal Reference Intervals for Glucose in Cerebrospinal Fluid Specimens.
N. V. Tolan, S. M. Jenkins, D. R. Block. Mayo Clinic, Rochester, MN, Poster Session
09. Electrolytes/Blood Gas/Metabolites
Tue, Jul 17, 2:00 - 4:30 PM
Tue, Jul 17, 10:00 AM - 12:30 PM
A-140/A-140 - Validation of Alpha 1-antitrypsin genotyping to identify Pi*S and Pi*Z alleles using Real-time PCR
S. S. Sam1, E. W. Highsmith2, G. J. Tsongalis1, J. A. Lefferts11Dartmouth Hitchcock Medical Center, Lebanon, NH, 2Laboratory Genetics, Mayo Clinic, Rochester, MN, Poster Session
04. Molecular Pathology/Probes
Tue, Jul 17, 10:00 AM - 12:30 PM
Tue, Jul 17, 10:00 AM - 12:30 PM
A-87/A-87 - Validation of Ultracentrifugation of Lipemic Serum Samples for Chemistry and Immunoassay Testing on the Roche Modular Platform
J. Mueller, L. Ouverson, N. A. Baumann, D. R. Block. Mayo Clinic, Rochester, MN, Poster Session
03. Lipids/Lipoproteins
Tue, Jul 17, 10:00 AM - 12:30 PM
Wed, Jul 18, 10:00 AM - 12:30 PM
C-160/C-160 - Analysis of patients with gamma heavy chain disease by heavy/light chain immunoglobulin investigation
E. Kaleta, R. Clark, J. Katzmann. Mayo Clinic, Rochester, MN, Poster Session
12. Immunology
Wed, Jul 18, 10:00 AM - 12:30 PM
Tue, Jul 17, 10:00 AM - 12:30 PM
A-146/A-146 - Development of a Sequencing Assay for New Pheochromocytoma Susceptibility TMEM127 gene
D. Milosevic, A. Algeciras-Schimnich, S. Grebe. Mayo Clinic and Foundation, Rochester, MN, Poster Session
04. Molecular Pathology/Probes
Tue, Jul 17, 10:00 AM - 12:30 PM
Wed, Jul 18, 10:00 AM - 12:30 PM
C-180/C-180 - Impact of a universal inpatient transcutaneous bilirubin screening program on the distribution of serum bilirubin values among healthy neonates at a single institution
B. S. Karon, A. C. Wickremasinghe, W. J. Cook. Mayo Clinic, Rochester, MN, Poster Session
13. Pediatric/Fetal Clinical Chemistry
Wed, Jul 18, 10:00 AM - 12:30 PM
Tue, Jul 17, 2:00 - 4:30 PM
B-36/B-36 - Performance Evaluation of the Roche c8000 On-board Quality Control Function
D. A. Dalenberg, D. R. Block, N. A. Baumann. Mayo Clinic and Foundation, Rochester, MN, Poster Session
06. Automation/Computer Applications
Tue, Jul 17, 2:00 - 4:30 PM
Tue, Jul 17, 10:00 AM - 12:30 PM
A-117/A-117 - Quantitation of Erythrocyte Omega-3 Fatty Acids Using On-Line Extraction and Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS).
A. J. Lueke, R. Bolterman, A. Saenger.Mayo Clinic Rochester, Rochester, MN, Poster Session
03. Lipids/Lipoproteins
Tue, Jul 17, 10:00 AM - 12:30 PM
Tue, Jul 17, 10:00 AM - 12:30 PM
A-75/A-75 - Validation of a Process Improvement for Streamlining Collection and Processing of Blood Collections for Lactate Analysis
D. A. Dalenberg, D. R. Block, N. A. Block. Mayo Clinic and Foundation, Rochester, MN, Poster Session
02. Factors Affecting Test Results
Tue, Jul 17, 10:00 AM - 12:30 PM
Tue, Jul 17, 10:00 AM - 12:30 PM
A-65/A-65 - Evaluation of Biotin Interference in Beckman Coulter Immunoassays that Use Biotin-Streptavidin in their Assay Design
J. P. Theobald, A. Algeciras-Schimnich.Mayo Clinic, Rochester, MN, Poster Session
02. Factors Affecting Test Results
Tue, Jul 17, 10:00 AM - 12:30 PM
Tue, Jul 17, 10:00 AM - 12:30 PM
A-175/A-175 - Discordant Cytochrome P450 2C19 (CYP2C19) Genotype versus platelet function pharmacodynamics assessement in a Clopidogrel non-responder.
K. J. Yeo1, D. J. O'Kane2, T. Ha1, S. Nathan1, C. C. Lee1, K. Mikrut1, J. L. Miller11University of Chicago, Chicago, IL, 2Mayo Clinic, Rochester, MN, Poster Session
04. Molecular Pathology/Probes
Tue, Jul 17, 10:00 AM - 12:30 PM
Wed, Jul 18, 10:00 AM - 12:30 PM
C-26/C-26 - Evaluation of Prostate Volume and [-2]proPSA for Prostate Cancer Detection, Using the Beckman Coulter Access 2 Immunoassay System, in a Multi-Center Prospective Clinical Trial
L. J. Sokoll1, D. W. Chan1, L. S. Marks2, K. M. Slawin3, C. H. Bangma4, R. H. N. van Schaik4, W. L. Roberts5, G. G. Klee6, J. T. Wei7, M. G. Sanda8, D. L. Broyles9, A. B. Cruz9, I. A. Mizrahi9, S. S. Shin9, A. W. Partin1, W. J. Catalona101Johns Hopkins Medical Institutions, Baltimore, MD, 2UCLA, Los Angeles, CA, 3Vanguard Urologic Institute and Texas Prostate Center, Houston, TX, 4Erasmus University Medical Center, Rotterdam, Netherlands, 5ARUP Laboratories, Salt Lake City, UT, 6Mayo Clinic, Rochester, MN, 7University of Michigan, Ann Arbor, MI, 8Beth Israel Deaconess Medical Center, Boston, MA, 9Beckman Coulter Incorporated, Carlsbad, CA,10Northwestern University, Chicago, IL, Poster Session
10. Cancer/Tumor Markers
Wed, Jul 18, 10:00 AM - 12:30 PM
mayocliniclabs

Mayo Medical Laboratories

This post was authored by the Marketing Team at Mayo Medical Laboratories.